RemeGen
荣昌生物
elsewhere's corpus doesn't carry a real profile of RemeGen. The only substantive mention comes from a July 2025 Qiming Venture Partners weekly roundup, where Mes Health CEO Wang Shuai — announcing a strategic partnership between Mes Health and RemeGen — called 荣昌生物 "a benchmark in China's innovative drug sector with strong performance in global innovative drug R&D competition," with the two planning to collaborate on full-lifecycle drug management . That characterizes RemeGen's standing through a partner's praise rather than describing the company itself; elsewhere has no coverage of its founding, pipeline, or financings.
AI-generated — may contain errors, please verify.
Coverage
Qiming View | Qiming Venture Partners' Kan Chen: Innovative Drug Primary Market Recovers, Bullish on Domestic FIC Innovative Drugs
Qiming Venture Partners will continue to stand by exceptional companies with a long-term mindset, helping them navigate cycles and expand globally.
Qiming Weekly | Qiming Venture Partners Portfolio Companies Funding and Updates Vol. 23, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Perspective | Qiming Venture Partners' Kan Chen: China's Innovative Drug Exports Hit Record Highs, Where Is Innovative Drug Investment Heading?
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
The Most Under-the-Radar Healthcare Fund: 13 Years, 10 Billion RMB, DPI Over 3 | RuJu
Technological upheaval, capital reallocation, and the tangled roots of an era have together forged this intricate commercial world. Between innovation and capital, as once-reliable operating models face new challenges and inherited industry norms—long carried west to east—come undone, people urgently seek a new map and a new order.
